Trial Profile
A Retrospective Cohort Study of the Efficacy and Evolution of Comorbidities With the Combination of Raltegravir and Boosted Darunavir in Suppressed HIV-infected Patients With Intolerance or Toxicity to Nucleoside Analogues
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Darunavir (Primary) ; Raltegravir (Primary) ; Cobicistat; Ritonavir
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms BIRDi
- 29 Jun 2018 Status changed from recruiting to completed.
- 22 Nov 2017 New trial record